Feature | August 30, 2012

Peripheral Vascular Procedures Moving Increasingly to Outpatient Setting

Millennium Research Group’s new physician forum report provides details of physician attitudes and choices

August 30, 2012 — According to Millennium Research Group (MRG), an authority on the medical technology market, as significant numbers of peripheral vascular and vascular access procedures move out of the hospital setting and into a variety of outpatient facilities, manufacturers of peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloons, atherectomy devices, thrombectomy devices and dialysis catheters will face new and complex challenges in marketing their products.

Physician preference is the main driving force in moving procedures into these facilities. Aside from the increased flexibility in scheduling procedures, physicians are particularly interested in the favorable reimbursement they receive for these procedures. Specialized vascular access centers have sprung up in the past five to 10 years, but many of these procedures are also performed in physician offices and in existing dialysis centers. The range of facility types is wide, making it difficult for manufacturers to target them effectively.

Physicians who run their own centers tend to have limited brand loyalty, but do keep a sharp eye on the bottom line, creating incentives for manufacturers to offer attractive pricing. If manufacturers are to succeed in appealing to this market, they need a deeper understanding of how these physicians acquire information and make purchasing decisions.

These results come from a new MRG report, Outpatient Vascular Treatment Centers Study, part of its Physician Forum series. Physician Forum reports are produced in response to specific market events and trends that are expected to have significant effects on the utilization and sales of medical devices. This report was published in June 2012.

The results are based on surveys that were conducted from March to May 2012 and included 90 respondents in vascular access centers, office-based practices and dialysis centers who have performed a significant number of interventional procedures. Survey respondents were interventional cardiologists, interventional nephrologists, interventional radiologists, nephrologists and vascular surgeons in the United States.

“There is a lot of variation between which procedures different centers and practices will be focusing on in the near future,” said MRG Manager Stephanie LaBelle. “Some are looking to increase their volume of lucrative vein treatments such as varicose vein ablation and sclerotherapy, while others will be specializing in peripheral artery disease, and expanding their atherectomy procedure volumes. Manufacturers need to make sure they have the most updated information on this rapidly changing market.”

Millennium Research Group’s Outpatient Vascular Treatment Centers Study report provides information about physician attitudes and purchase decision criteria for peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloons, atherectomy devices, thrombectomy devices and dialysis catheters used in vascular access centers, office-based practices and dialysis centers.

For more information: www.MRG.net

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init